<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0217513</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1037</journal-id>
<journal-id journal-id-type="nlm-ta">Biochim Biophys Acta</journal-id>
<journal-id journal-id-type="iso-abbrev">Biochim. Biophys. Acta</journal-id>
<journal-title-group>
<journal-title>Biochimica et biophysica acta</journal-title>
</journal-title-group>
<issn pub-type="ppub">0006-3002</issn>
<issn pub-type="epub">1878-2434</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27919711</article-id>
<article-id pub-id-type="pmc">5222695</article-id>
<article-id pub-id-type="doi">10.1016/j.bbadis.2016.11.030</article-id>
<article-id pub-id-type="manuscript">NIHMS835491</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Epigenetic Dysfunctional Diseases and Therapy for Infection and Inflammation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Samanta</surname>
<given-names>Saheli</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rajasingh</surname>
<given-names>Sheeja</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cao</surname>
<given-names>Thuy</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dawn</surname>
<given-names>Buddhadeb</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rajasingh</surname>
<given-names>Johnson</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Internal Medicine, Cardiovascular Research Institute, University of Kansas Medical Center, Kansas City, KS, USA</aff>
<aff id="A2"><label>2</label>Department of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, KS, USA</aff>
<author-notes>
<corresp id="FN1"><label>*</label>Address correspondence to: Johnson Rajasingh Ph.D., Assistant Professor, Cardiovascular Research Institute, Department of Internal Medicine and Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, KS 66160, <email>rjohnson9@kumc.edu</email>, Phone: 913-945-7759; Fax: 913-945-7037</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>13</day>
<month>12</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>03</day>
<month>12</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>2</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>2</month>
<year>2018</year>
</pub-date>
<volume>1863</volume>
<issue>2</issue>
<fpage>518</fpage>
<lpage>528</lpage>
<!--elocation-id from pubmed: 10.1016/j.bbadis.2016.11.030-->
<abstract id="Abs1">
<p id="P1">Even though the discovery of the term ‘epigenetics’ was in the 1940s, it has recently become one of the most promising and expanding fields to unravel the gene expression pattern in several diseases. The most well studied example is cancer, but other diseases like metabolic disorders, autism, or inflammation-associated diseases such as lung injury, autoimmune disease, asthma, and type-2 diabetes display aberrant gene expression and epigenetic regulation during their occurrence. The change in the epigenetic pattern of a gene may also alter gene function because of a change in the DNA status. Constant environmental pressure, lifestyle, as well as food habits are the other important parameters responsible for transgenerational inheritance of epigenetic traits. Discovery of epigenetic modifiers targeting DNA methylation and histone deacetylation enzymes could be an alternative source to treat or manipulate the pathogenesis of diseases. Particularly, the combination of epigenetic drugs such as 5-Aza-2-deoxycytidine (Aza) and trichostatin A (TSA) are well studied to reduce inflammation in an acute lung injury model. It is important to understand the epigenetic machinery and the function of its components in specific diseases to develop targeted epigenetic therapy. Moreover, it is equally critical to know the specific inhibitors other than the widely used pan inhibitors in clinical trials and explore their roles in regulating specific genes in a more defined way during infection.</p>
</abstract>
<abstract abstract-type="graphical" id="Abs2">
<title>Graphical abstract</title>
<p id="P2">
<graphic orientation="portrait" position="anchor" xlink:href="nihms835491u1.jpg"></graphic></p>
</abstract>
<kwd-group>
<kwd>epigenetic modifier</kwd>
<kwd>DNA methyl transferase</kwd>
<kwd>Histone deacetylase</kwd>
<kwd>5-Aza-2-deoxycytidine</kwd>
<kwd>trichostatin A</kwd>
<kwd>inflammation</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>